HEPION PHARMACEUTICALS, INC. Operating Cash Flow
HEPION PHARMACEUTICALS, INC. (HEPA) reported Operating Cash Flow of -$815.37 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-13
- HEPION PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$1.39M.
- HEPION PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was $578.58K.
- HEPION PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$332.77K.
- HEPION PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$445.96K.
- HEPION PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$3.27M.
- HEPION PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$18.22M.
- HEPION PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$40.89M.
- HEPION PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$34.96M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$815.37K 10-Q · filed 2026-08-13 | -$1.15M derived: sum of 3 quarters · filed 2026-08-13 | -$1.59M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $578.58K 10-Q · filed 2026-05-14 | $245.81K derived: sum of 2 quarters · filed 2026-05-14 | -$200.15K derived: sum of 3 quarters · filed 2026-05-14 | -$1.58M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$332.77K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$778.74K derived: sum of 2 quarters · filed 2026-03-12 | -$2.15M derived: sum of 3 quarters · filed 2026-08-13 | -$3.27M 10-K · filed 2026-03-12 |
| 2025-09-30 | -$445.96K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$1.82M derived: sum of 2 quarters · filed 2026-08-13 | -$2.94M 10-Q · filed 2025-11-12 | -$4.09M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$1.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$2.49M 10-Q · filed 2026-08-13 | -$3.65M derived: sum of 3 quarters · filed 2026-08-13 | -$6.16M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$1.12M 10-Q · filed 2026-05-14 | -$2.27M derived: sum of 2 quarters · filed 2026-05-14 | -$4.79M derived: sum of 3 quarters · filed 2026-05-14 | -$15.72M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$1.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$3.67M derived: sum of 2 quarters · filed 2026-03-12 | -$14.60M derived: sum of 3 quarters · filed 2026-03-12 | -$18.22M 10-K · filed 2026-03-12 |
| 2024-09-30 | -$2.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$13.45M derived: sum of 2 quarters · filed 2025-11-12 | -$17.06M 10-Q · filed 2025-11-12 | -$26.07M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$10.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$14.55M 10-Q · filed 2025-08-14 | -$23.55M derived: sum of 3 quarters · filed 2025-08-14 | -$34.78M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$3.62M 10-Q · filed 2025-05-19 | -$12.62M derived: sum of 2 quarters · filed 2025-05-19 | -$23.85M derived: sum of 3 quarters · filed 2025-05-19 | -$36.29M derived: sum of 4 quarters · filed 2025-05-19 |
| 2023-12-31 | -$9.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-08 | -$20.24M derived: sum of 2 quarters · filed 2025-04-08 | -$32.67M derived: sum of 3 quarters · filed 2025-04-08 | -$40.89M 10-K · filed 2025-04-08 |
| 2023-09-30 | -$11.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$23.67M derived: sum of 2 quarters · filed 2024-11-14 | -$31.89M 10-Q · filed 2024-11-14 | -$36.68M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$12.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$20.65M 10-Q · filed 2024-08-13 | -$25.45M derived: sum of 3 quarters · filed 2024-08-13 | -$37.98M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$8.21M 10-Q · filed 2024-05-21 | -$13.01M derived: sum of 2 quarters · filed 2024-05-21 | -$25.55M derived: sum of 3 quarters · filed 2024-05-21 | -$33.05M derived: sum of 4 quarters · filed 2024-05-21 |
| 2022-12-31 | -$4.80M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-16 | -$17.33M derived: sum of 2 quarters · filed 2024-04-16 | -$24.83M derived: sum of 3 quarters · filed 2024-04-16 | -$34.96M 10-K · filed 2024-04-16 |
| 2022-09-30 | -$12.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-20 | -$20.03M derived: sum of 2 quarters · filed 2023-11-20 | -$30.16M 10-Q · filed 2023-11-20 | -$37.55M derived: sum of 4 quarters · filed 2023-11-20 |
| 2022-06-30 | -$7.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$17.63M 10-Q · filed 2023-08-14 | -$25.01M derived: sum of 3 quarters · filed 2023-08-14 | -$36.33M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$10.13M 10-Q · filed 2023-05-12 | -$17.51M derived: sum of 2 quarters · filed 2023-05-12 | -$28.83M derived: sum of 3 quarters · filed 2023-05-12 | -$34.00M derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | -$7.38M derived: 10-K 12 month − 10-Q 9 month · filed 2023-04-10 | -$18.71M derived: sum of 2 quarters · filed 2023-04-10 | -$23.88M derived: sum of 3 quarters · filed 2023-04-10 | -$31.22M 10-K · filed 2023-04-10 |
| 2021-09-30 | -$11.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$16.49M derived: sum of 2 quarters · filed 2022-11-14 | -$23.84M 10-Q · filed 2022-11-14 | -$28.37M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$5.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$12.52M 10-Q · filed 2022-08-15 | -$17.04M derived: sum of 3 quarters · filed 2022-08-15 | -$20.89M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | -$7.35M 10-Q · filed 2022-05-16 | -$11.87M derived: sum of 2 quarters · filed 2022-05-16 | -$15.73M derived: sum of 3 quarters · filed 2022-05-16 | -$18.84M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | -$4.53M derived: 10-K 12 month − 10-Q 9 month · filed 2022-04-08 | -$8.38M derived: sum of 2 quarters · filed 2022-04-08 | -$11.49M derived: sum of 3 quarters · filed 2022-04-08 | -$16.17M 10-K · filed 2022-04-08 |
| 2020-09-30 | -$3.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | -$6.96M derived: sum of 2 quarters · filed 2021-11-15 | -$11.64M 10-Q · filed 2021-11-15 | -$14.08M derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | -$3.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | -$7.79M 10-Q · filed 2021-08-16 | -$10.23M derived: sum of 3 quarters · filed 2021-08-16 | -$12.03M derived: sum of 4 quarters · filed 2021-08-16 |
| 2020-03-31 | -$4.68M 10-Q · filed 2021-05-14 | -$7.12M derived: sum of 2 quarters · filed 2021-05-14 | -$8.92M derived: sum of 3 quarters · filed 2021-05-14 | -$10.18M derived: sum of 4 quarters · filed 2021-05-14 |
| 2019-12-31 | -$2.44M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | -$4.24M derived: sum of 2 quarters · filed 2021-03-31 | -$5.51M derived: sum of 3 quarters · filed 2021-03-31 | -$7.57M 10-K · filed 2021-03-31 |
| 2019-09-30 | -$1.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | -$3.07M derived: sum of 2 quarters · filed 2020-11-16 | -$5.12M 10-Q · filed 2020-11-16 | -$10.22M derived: sum of 4 quarters · filed 2020-11-16 |
| 2019-06-30 | -$1.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | -$3.32M 10-Q · filed 2020-08-12 | -$8.41M derived: sum of 3 quarters · filed 2020-08-12 | -$11.96M derived: sum of 4 quarters · filed 2020-08-12 |
| 2019-03-31 | -$2.06M 10-Q · filed 2020-06-29 | -$7.15M derived: sum of 2 quarters · filed 2020-06-29 | -$10.69M derived: sum of 3 quarters · filed 2020-06-29 | -$14.11M derived: sum of 4 quarters · filed 2020-06-29 |
| 2018-12-31 | -$5.09M derived: 10-K 12 month − 10-Q 9 month · filed 2020-05-14 | -$8.64M derived: sum of 2 quarters · filed 2020-05-14 | -$12.05M derived: sum of 3 quarters · filed 2020-05-14 | -$15.65M 10-K · filed 2020-05-14 |
| 2018-09-30 | -$3.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | -$6.96M derived: sum of 2 quarters · filed 2019-11-14 | -$10.55M 10-Q · filed 2019-11-14 | -$13.39M derived: sum of 4 quarters · filed 2019-11-14 |
| 2018-06-30 | -$3.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | -$7.01M 10-Q · filed 2019-08-14 | -$9.85M derived: sum of 3 quarters · filed 2019-08-14 | -$15.22M derived: sum of 4 quarters · filed 2019-08-14 |
| 2018-03-31 | -$3.59M 10-Q · filed 2019-05-15 | -$6.43M derived: sum of 2 quarters · filed 2019-05-15 | -$11.80M derived: sum of 3 quarters · filed 2019-05-15 | -$16.05M derived: sum of 4 quarters · filed 2019-05-15 |
| 2017-12-31 | -$2.84M derived: 10-K 6 month − 10-Q 3 month · filed 2019-03-14 | -$8.21M 10-K · filed 2019-03-14 | -$12.46M derived: sum of 3 quarters · filed 2019-03-14 | -$17.67M derived: sum of 4 quarters · filed 2019-03-14 |
| 2017-09-30 | -$5.37M 10-Q · filed 2017-11-14 | -$9.62M derived: sum of 2 quarters · filed 2018-08-14 | -$14.84M 10-Q · filed 2018-11-14 | |
| 2017-06-30 | -$4.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14 | -$9.46M 10-Q · filed 2018-08-14 | -$19.17M 10-K · filed 2019-03-14 | |
| 2017-03-31 | -$5.22M 10-Q · filed 2018-05-15 | |||
| 2016-09-30 | -$4.38M 10-Q · filed 2017-11-14 | |||
| 2016-06-30 | -$16.56M 10-KT · filed 2018-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |